NCE-1 Intelligence & Market Opportunity

Voranigo

Vorasidenib

Anticancer

Oral Tablets

Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens

Approval Date

06-Aug-24

NCE-1 Date

06-Aug-28

NCE Date

06-Aug-29

Commercial snapshot

Market performance & projections

Revenue ($M)

561

CAGR (%)

48.99%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1,385

2027

2,006

2028

2,417

2029

2,764

2030

3,070

2031

3,391

2032

3,673

Molecule profile

Details & specifications

Molecule

Vorasidenib

Innovator

SERVIER PHARMACEUTICALS LLC

Dosage Form

Oral Tablets

Strength

10 mg and 40 mg

Therapeutic Category

Anticancer

Usage

To treat grade 2 astrocytoma or oligodendroglioma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets